Main Menu

Managing Partner Peter Venaglia to Speak at Upcoming Program on Pharmaceutical Compliance

January 5, 2016
Filed under: Compliance, News

The firm’s Managing Partner, Peter Venaglia, has been invited to lead an interactive workshop at the American Conference Institute’s 16th Annual Forum on Fraud and Abuse in the Sales and Marketing of Drugs: Fortifying Compliance Protocols to Prepare for Changing Enforcement Priorities.  The workshop, which is entitled an “Interactive Working Group on Upgrading Your Pharmaceutical Compliance Program,” will be held on the second day of the conference, Thursday, March 10, 2016, starting at 2 p.m., at the Omni Parker House in Boston, Massachusetts.  Peter will lead the workshop along with Holly Pierson, the Owner and Managing Partner of Pierson Law in Atlanta, Georgia.

Among the topics that will be addressed at the workshop are:

  • Preparing C-Suite executives for increased prosecution of individuals in the pharmaceutical industry.
  • Updating your training programs to prepare sales teams and consultants for heightened individual prosecution.
  • Implementing risk assessment and mitigation programs (RAMPs).
  • Negotiating, preparing for and ensuring compliance with Corporate Integrity Agreements.
  • Adapting compliance protocols for small and medium sized pharmaceutical companies.
  • Compliance programs in the M&A context.
  • The False Claims Act: lessons learned from this year’s biggest prosecutions against pharmaceutical companies.
  • Best practices for drafting contracts that satisfy your HCP’s needs while protecting your interests.
  • Conducting internal audits and ensuring confidentiality.
  • Best practices to remain in compliance with HIPAA and other privacy laws.
  • Considerations for expanding your pipeline to include medical or combination devices.

Those interested in attending the conference can contact the American Conference Institute at 888-224-2480 or visit  Continuing Legal Education credit is available through the American Conference Institute.

No comments yet.

Leave a Reply